Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTRN12615000276550Phase 2Recruiting
Phase 2, open-label trial of ropivacaine and budesonide in chronic rhinosinusitis (CRS) (2 arms), sponsored by University of Adelaide. Primary endpoint: Postoperative pain. Started Mar 2015; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ACTRN12615000276550.